ArticleHereditas2025
Prognostic analysis of bladder cancer with neddylation-related genes.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overexpression of MFAP4 inhibits the proliferation, migration, and invasion of bladder cancer cells.Discover oncology · 2026Article
- Post-translational modifications: Principal regulators of bladder cancer.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have demonstrated a close association between neddylation modifications and tumor progression as well as alterations in the microenvironment. This study aimed to explore the role of neddylation in bladder cancer (BLCA) progression and its prognostic significance.
methodsGene expression data from the TCGA database were analyzed to identify neddylation gene modules using the limma software package and weighted gene co-expression network analysis (WGCNA). Prognostic models based on neddylation-related genes were subsequently developed through LASSO and Cox regression analyses. Additionally, a protein-protein interaction (PPI) network, gene set enrichment analysis (GSEA), and BLCA single-cell sequencing data were utilized to explore the functional roles of hub genes in BLCA and their impact on biological pathways. The expression of these hub genes was further validated in clinical samples via RT-qPCR.
resultsWGCNA analysis revealed 1412 neddylation-related hub genes. LASSO and Cox regression analyses subsequently identified six key genes: CUL1, PUM2, UBE2D3, HIF3A, COPS2, and DDB1. Transcriptomic data and RT-qPCR findings indicated that PUM2 and HIF3A exhibited high expression levels in normal tissues, while DDB1 showed increased expression in tumor tissues; no significant changes were observed for CUL1, COPS2, and UBE2D3. By integrating these gene expressions with significant clinical features, a prognostic model was constructed that demonstrated excellent diagnostic efficiency (AUC: 0.793 at 1 year, 0.792 at 3 years, and 0.773 at 5 years). In addition, single cell sequencing highlighted the potential role of these genes in modulating immune responses and mediating interactions between tumor cells and immune cells. GSEA also suggested that DDB1 may play a crucial role in orchestrating key biological processes associated with BLCA, particularly in activating apoptotic signaling pathways.
conclusionThe six neddylation-related genes (CUL1, PUM2, UBE2D3, HIF3A, COPS2, and DDB1) emerge as potential independent indicators of survival in patients with BLCA, and the constructed survival models exhibit significant diagnostic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.